PHI är ett medicintekniskt bolag som utvecklar och marknadsför icke-invasiva time-lapse imaging-inst...
Synthetic MR har ett utmanande 2024 med nettoomsättning för Q3 på 13,3 MSEK (-39% YoY) fortsatt driv...
Signs of market improving from low levels Good activity with Aira, but new partnerships will take ti...
XP Chemistries fick en RFI (request for information) från EFSA (European Food Safety Authority) gäll...
Redeye is encouraged by the announcement of a strategic restructuring of Champion Health Plus.
European recovery seems to continue Low market share and strong offering provide long runway for gro...
AcuCort AB (”AcuCort” eller ”Bolaget”) har under Q3-24 tagit viktiga steg i kommersialiseringsresan,...
Starbreeze has announced a partnership with Krafton, the South Korean gaming giant behind PUBG.
Beyond Frames has unveiled that one of their ongoing projects is based on the multi-billion dollar I...
Redeye returns with a more in-depth take on the report following the conference call and chat with m...
Capitalising on the wave of infrastructure and defence investments 58% adj.
We have analised Verrica's funding and update our base case for Lytix based on Verrica's improved fi...
On December 4th ODI Pharma provided an update regarding Poland’s expanding medical cannabis market.
The company upgraded its 2024 net sales guidance midpoint by 5% on December 4.
MoveByBike Europe AB (”MoveByBike” eller ”Bolaget”) är ett hållbart logistikföretag som erbjuder hål...
Redeye discusses Alligator Bioscience's rights issue announced on 2 January.
Redeye comments on the news that Egetis has decided to explore RTH-beta as the next indiction for ti...
Hansa’s partner Genethon initiates a phase 2 study based on Imlifidase as a pre-treatment ahead of G...
Redeye sees a Q2 report in line with our sales expectations but a bit heavier on the cost side.
Redeye updates on Maximum Entertainment following its Q3-results which were weaker than expected.
